Table 4. . Summary of base case findings.
| rt-CGM | SMBG | Difference | |
|---|---|---|---|
| Total mean lifetime costs, CAD | 207,466 | 189,863 | 17,602 |
| Treatment costs, CAD | 51,305 | 15,323 | 35,983 |
| Management costs, CAD | 5931 | 5790 | 141 |
| Cardiovascular complication costs, CAD | 35,088 | 35,224 | -136 |
| Renal complication costs, CAD | 94,137 | 110,352 | -16,215 |
| Ulcer/amputation/neuropathy complication costs, CAD | 7123 | 7372 | -249 |
| Ophthalmic complication costs, CAD | 13,882 | 14,228 | -347 |
| Severe hypoglycemia costs, CAD | 0 | 1272 | -1272 |
| Diabetic ketoacidosis costs, CAD | 0 | 303 | -303 |
| Mean quality-adjusted life expectancy, QALYs | 9.971 | 9.021 | 0.950 |
| ICUR, CAD per QALY gained | 18,523 | ||
| Probability of rt-CGM being cost-effective vs SMBG at a WTP threshold of CAD 50,000 per QALY gained (%) | 67.1 |
CAD: Canadian Dollar; ICUR: Incremental cost-utility ratio; QALY: Quality-adjusted life year; rt-CGM: Real-time continuous glucose monitoring; SMBG: Self-monitoring of blood glucose; WTP: Willingness-to-pay.